MENU
+Compare
DMAC
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$5.71
Change
+$0.04 (+0.71%)
Capitalization
244.16M

DMAC DiaMedica Therapeutics Forecast, Technical & Fundamental Analysis

a developer of novel therapeutic compounds for diabetes and other diseases

Industry Biotechnology
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for DMAC with price predictions
Jan 14, 2025

Aroon Indicator for DMAC shows an upward move is likely

DMAC's Aroon Indicator triggered a bullish signal on December 31, 2024. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 187 similar instances where the Aroon Indicator showed a similar pattern. In of the 187 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DMAC advanced for three days, in of 249 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for DMAC moved out of overbought territory on December 23, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on January 13, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on DMAC as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for DMAC turned negative on December 23, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DMAC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

DMAC broke above its upper Bollinger Band on December 20, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DMAC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.092) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (87.786). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.852). DMAC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (263.573).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DMAC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

DMAC is expected to report earnings to rise 15.00% to -17 cents per share on March 25

DiaMedica Therapeutics DMAC Stock Earnings Reports
Q4'24
Est.
$-0.17
Q3'24
Beat
by $0.01
Q2'24
Beat
by $0.03
Q1'24
Beat
by $0.02
Q4'23
Beat
by $0.02
The last earnings report on November 13 showed earnings per share of -15 cents, beating the estimate of -15 cents. With 249.08K shares outstanding, the current market capitalization sits at 244.16M.
A.I. Advisor
published General Information

General Information

a developer of novel therapeutic compounds for diabetes and other diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
301 Carlson Parkway
Phone
+1 763 496-5454
Employees
19
Web
https://www.diamedica.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

DMAC and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with AADI. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then AADI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMAC
1D Price
Change %
DMAC100%
+0.71%
AADI - DMAC
41%
Loosely correlated
-4.79%
VICP - DMAC
33%
Poorly correlated
-70.71%
CYYNF - DMAC
30%
Poorly correlated
N/A
CSLLY - DMAC
26%
Poorly correlated
+0.38%
PCVX - DMAC
26%
Poorly correlated
-2.88%
More